India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has approved a wide range of recombinant DNA (r-DNA)-origin drugs and biologics for manufacture ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

The oncology market in the United States was estimated at $81.34 billion in 2025 and is expected to reach $211.78 billion by ...

Acceptance of respiratory syncytial virus (RSV) immunizations in the United States is growing, particularly for older adults, ...

MOSCOW. Jan 21 (Interfax) - The share of Russian-made medicines on the domestic pharmaceutical market is 63%, and that on the government procurement market 80%, Industry and Trade Minister Anton ...

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

GSK plc GSK announced that it has entered into a definitive agreement to acquire California-based biotech RAPT Therapeutics ...

A look at the clinical progress of anti-Aβ monoclonal antibodies and how precision delivery is shaping the next generation of ...

Researchers found an antibody that seems to play a role in people with better lung cancer prognoses, but turning it into a ...

The FDA has granted breakthrough therapy designation to Novartis’ ianalumab for Sjögren’s disease, according to a press release from the manufacturer.In its statement, Novartis said it plans to submit ...

Novartis received breakthrough therapy designation from the FDA for ianalumab, a monoclonal antibody aimed at treating Sjögren’s disease. Ianalumab works by depleting B cells and blocking BAFF-R ...

NICE has recommended obinutuzumab with mycophenolate for severe lupus nephritis after trials showed higher renal response and fewer flares.